Cargando…

Modulation of Intestinal Microbiota by the Probiotic VSL#3 Resets Brain Gene Expression and Ameliorates the Age-Related Deficit in LTP

The intestinal microbiota is increasingly recognized as a complex signaling network that impacts on many systems beyond the enteric system modulating, among others, cognitive functions including learning, memory and decision-making processes. This has led to the concept of a microbiota-driven gut–br...

Descripción completa

Detalles Bibliográficos
Autores principales:	Distrutti, Eleonora, O’Reilly, Julie-Ann, McDonald, Claire, Cipriani, Sabrina, Renga, Barbara, Lynch, Marina A., Fiorucci, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159266/ https://www.ncbi.nlm.nih.gov/pubmed/25202975 http://dx.doi.org/10.1371/journal.pone.0106503

Ejemplares similares

VSL#3 Resets Insulin Signaling and Protects against NASH and Atherosclerosis in a Model of Genetic Dyslipidemia and Intestinal Inflammation
por: Mencarelli, Andrea, et al.
Publicado: (2012)

Probiotics VSL#3 Protect against Development of Visceral Pain in Murine Model of Irritable Bowel Syndrome
por: Distrutti, Eleonora, et al.
Publicado: (2013)

Probiotics Modulate Intestinal Expression of Nuclear Receptor and Provide Counter-Regulatory Signals to Inflammation-Driven Adipose Tissue Activation
por: Mencarelli, Andrea, et al.
Publicado: (2011)

Divergent Effectiveness of Multispecies Probiotic Preparations on Intestinal Microbiota Structure Depends on Metabolic Properties
por: Biagioli, Michele, et al.
Publicado: (2019)

Hydrogen sulphide induces μ opioid receptor-dependent analgesia in a rodent model of visceral pain
por: Distrutti, Eleonora, et al.
Publicado: (2010)

The Bile Acid Sensor FXR Protects against Dyslipidemia and Aortic Plaques Development Induced by the HIV Protease Inhibitor Ritonavir in Mice
por: Mencarelli, Andrea, et al.
Publicado: (2010)

Amelioration of intestinal and systemic sequelae of murine Campylobacter jejuni infection by probiotic VSL#3 treatment
por: Ekmekciu, Ira, et al.
Publicado: (2017)

The Bile Acid Receptor GPBAR-1 (TGR5) Modulates Integrity of Intestinal Barrier and Immune Response to Experimental Colitis
por: Cipriani, Sabrina, et al.
Publicado: (2011)

Correction: The Bile Acid Receptor GPBAR-1 (TGR5) Modulates Integrity of Intestinal Barrier and Immune Response to Experimental Colitis
por: Cipriani, Sabrina, et al.
Publicado: (2013)

The Bile Acid Sensor FXR Is Required for Immune-Regulatory Activities of TLR-9 in Intestinal Inflammation
por: Renga, Barbara, et al.
Publicado: (2013)

Metabolic Variability of a Multispecies Probiotic Preparation Impacts on the Anti-inflammatory Activity
por: Biagioli, Michele, et al.
Publicado: (2017)

Dissociation of Intestinal and Hepatic Activities of FXR and LXRα Supports Metabolic Effects of Terminal Ileum Interposition in Rodents
por: Mencarelli, Andrea, et al.
Publicado: (2013)

Decoding the role of the nuclear receptor SHP in regulating hepatic stellate cells and liver fibrogenesis
por: Cipriani, Sabrina, et al.
Publicado: (2017)

Comparative genomic analysis of the multispecies probiotic-marketed product VSL#3
por: Douillard, François P., et al.
Publicado: (2018)

Rapid ATF4 Depletion Resets Synaptic Responsiveness after cLTP
por: Amar, Fatou, et al.
Publicado: (2021)

The HIV matrix protein p17 induces hepatic lipid accumulation via modulation of nuclear receptor transcriptoma
por: Renga, Barbara, et al.
Publicado: (2015)

Solomonsterol A, a Marine Pregnane-X-Receptor Agonist, Attenuates Inflammation and Immune Dysfunction in a Mouse Model of Arthritis
por: Mencarelli, Andrea, et al.
Publicado: (2013)

Discovery of a Novel Multi-Strains Probiotic Formulation with Improved Efficacy toward Intestinal Inflammation
por: Biagioli, Michele, et al.
Publicado: (2020)

Correction: Comparative genomic analysis of the multispecies probiotic-marketed product VSL#3
por: Douillard, François P., et al.
Publicado: (2018)

Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases
por: Cheng, Fang-Shu, et al.
Publicado: (2020)

Probiotic Therapy With VSL#3(®) in Patients With NAFLD: A Randomized Clinical Trial
por: Derosa, Giuseppe, et al.
Publicado: (2022)

Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis
por: Mencarelli, Andrea, et al.
Publicado: (2016)

Nitric oxide protects against HIV gp120 endothelial injury
por: Fiorucci, S, et al.
Publicado: (2010)

Oral Probiotic VSL#3 Prevents Autoimmune Diabetes by Modulating Microbiota and Promoting Indoleamine 2,3-Dioxygenase-Enriched Tolerogenic Intestinal Environment
por: Dolpady, Jayashree, et al.
Publicado: (2016)

Corrigendum to “Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases”
por: Sang, Li-Xuan
Publicado: (2021)

Probiotic colonization dynamics after oral consumption of VSL#3(®) by antibiotic-treated mice
por: Theriot, Casey, et al.
Publicado: (2022)

Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH
por: Marchianò, Silvia, et al.
Publicado: (2023)

Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: A systematic review and meta-analysis
por: Dang, Xiaofei, et al.
Publicado: (2020)

Probiotics (VSL#3) Prevent Endothelial Dysfunction in Rats with Portal Hypertension: Role of the Angiotensin System
por: Rashid, Sherzad K., et al.
Publicado: (2014)

The Probiotic Mixture VSL#3 Accelerates Gastric Ulcer Healing by Stimulating Vascular Endothelial Growth Factor
por: Dharmani, Poonam, et al.
Publicado: (2013)

PReS-FINAL-2074: The role of the probiotic VSL-3 as adjuvant therapy in patients with undifferentiated spondyloarthritis (ERA)
por: Vidovic, M, et al.
Publicado: (2013)

Correction: Probiotics (VSL#3) Prevent Endothelial Dysfunction in Rats with Portal Hypertension: Role of the Angiotensin System
Publicado: (2014)

Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3
por: Vicari, Enzo, et al.
Publicado: (2014)

VSL#3 probiotic modifies mucosal microbial composition but does not reduce colitis-associated colorectal cancer
por: Arthur, Janelle C., et al.
Publicado: (2013)

Change of Fecal Flora and Effectiveness of the Short-term VSL#3 Probiotic Treatment in Patients With Functional Constipation
por: Kim, Seong-Eun, et al.
Publicado: (2015)

Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H(2)S Generation and Endothelin-1
por: Renga, Barbara, et al.
Publicado: (2015)

Development of omics‐based protocols for the microbiological characterization of multi‐strain formulations marketed as probiotics: the case of VSL#3
por: Mora, Diego, et al.
Publicado: (2019)

Probiotic VSL#3 Treatment Reduces Colonic Permeability and Abdominal Pain Symptoms in Patients With Irritable Bowel Syndrome
por: Boonma, Prapaporn, et al.
Publicado: (2021)

Correction: The Probiotic Mixture VSL#3 Accelerates Gastric Ulcer Healing by Stimulating Vascular Endothelial Growth Factor
por: Dharmani, Poonam, et al.
Publicado: (2022)

Bile Acids Activated Receptors Regulate Innate Immunity
por: Fiorucci, Stefano, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ove332t1tet49u0o7pnn82lj7e